Evidence map›Paper›PMID 42653238›Full record

ArticleInternational journal of molecular sciences2026

Structure-Activity Relationship for Inflammasome Inhibition by Thiomuscimol.

Marisa J Anderson, Wendy P Loomis, Andreas B den Hartigh, Bente Frølund, Susan L Fink

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marisa J AndersonDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Wendy P LoomisDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Andreas B den HartighDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Bente FrølundDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100-Ø Copenhagen, Denmark.
Susan L FinkDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-1705-0103

Funding

Role of IRE1 Alpha in Coronavirus InfectionsR01AI162684 · NIAID · UNIVERSITY OF WASHINGTON · PI Susan Leilani Fink · 2022 to 2026
$2.8M
Mechanism of Muscimol as a Novel Pyroptosis InhibitorR21AI178367 · NIAID · UNIVERSITY OF WASHINGTON · PI FINK, SUSAN LEILANI · 2023 to 2024
$428k
National Institute of Allergy and Infectious Diseases R01AI162684National Institute of Allergy and Infectious Diseases R21AI178367NIAID NIH HHS R01 AI162684NIAID NIH HHS R21 AI178367
6 · The paper itself

Abstract

Inflammasomes are central mediators of innate immune defense but can also drive pathological inflammation and pyroptotic cell death in numerous diseases. While several small-molecule inhibitors have been described, many selectively target individual inflammasomes or act through the adaptor protein ASC, leaving ASC-independent pathways unaffected. We previously identified thiomuscimol as a broad-spectrum inflammasome inhibitor that blocks both ASC-dependent and ASC-independent activation, although the structural basis for this activity remains unclear. Here, we examined the structure-activity relationship of thiomuscimol using related compounds and synthetic analogs. In primary macrophages, inflammasome activation and pyroptosis were assessed by live cell imaging of ASC speck formation, gasdermin D-mediated dye uptake, and cellular ATP levels. Structurally related sulfur-containing molecules, including taurine and isothiazole, failed to inhibit inflammasome activation, indicating that neither the sulfur in an electron-rich environment nor the heterocyclic scaffold confer activity. Replacement of the primary amine with a carbonyl group abolished activity, whereas substitution with a secondary amine preserved inhibitory potency comparable to thiomuscimol. Incorporation of the amine into an annulated piperidine ring reduced potency and revealed sensitivity to the precise positioning of the amine within the ring. Together, these findings identify key structural features required for thiomuscimol-mediated inflammasome inhibition and provide a framework for future studies to define its mechanism of action and guide the development of improved inhibitors.

Indexed as

InflammasomesAnimalsMacrophagesMicePyroptosisStructure-Activity RelationshipInflammasomesASCcaspase-1gasdermin Dinflammasomeinnate immunitypyroptosisstructure–activity relationshipthiomuscimol

Identifiers

PMID42653238
PMCPMC13513477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.